Trials / Completed
CompletedNCT04602884
Early Detection of COVID-19 Using Breath Analysis
Early Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis: First Cross-Sectional Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Scentech Medical Technologies Ltd · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
EARLY DETECTION OF COVID-19 USING BREATH ANALYSIS- FIRST CROSS-SECTIONAL STUDY
Detailed description
Primary objective- to identify and evaluate a set of biomarkers that represent both the genetic expression of the virus itself (SARS-CoV-2) and the metabolic activity of the immune system's response to the virus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Breath biopsy sampling using the ReCIVA Breath Sampler | Breath biopsy sampling using the ReCIVA Breath Sampler |
Timeline
- Start date
- 2020-09-22
- Primary completion
- 2021-12-30
- Completion
- 2021-12-30
- First posted
- 2020-10-26
- Last updated
- 2022-02-07
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT04602884. Inclusion in this directory is not an endorsement.